ISSN: 2332-0877

感染症と治療ジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

The Antimicrobial Therapy of the Future: Combating Resistances

Beatriz Suay-García and María Teresa Pérez-Gracia*

The appearance of antibiotic resistance is an increasing problem in our society, where the adaptation of microorganisms to conventional therapies has been favored due to their incorrect use. This has driven the scientific community to develop new therapeutic alternatives hoping to obtain treatments that are more effective against increasingly resistant bacteria. The purpose of this study is to review the existent knowledge on the therapeutic alternatives that are being developed to treat cases of infection with antibiotic resistant bacteria. To do so, scientific publications were consulted on the MEDLINE database using different search terms. The bibliography consulted indicates that a great variety of therapeutic alternatives are currently being developed among which the most relevant are probiotics, synthetic peptides, bacteriophages and nanoparticles. Some of these measures, such as probiotics, are already being introduced in some hospitals with positive results. Others, such as synthetic peptides, bacteriophages or nanoparticles are still in the early stages of development and clinical trials. Moreover, there is a clear tendency to go back to the more classical medicine turning to plant extracts and essential oils whose active ingredients have been proven to have therapeutic activity. This shift towards less conventional therapies is marking the beginning of a post-antibacterial era in which antibiotics will most probably be replaced for probiotics, bacteriophages, synthetic peptides or even inorganic nanoparticles.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。